Shares of Viking Therapeutics have sold off sharply as the market awaits updates on its drug candidates. The company is preparing for the possible FDA approval of its weight loss drug candidate VK2735 ...

People who have tried other methods to lose weight have found results from obesity drugs that ‘feel like magic.’ ...

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are tirzepatide (Zepbound) and semaglutide (Wegovy). Semaglutide was originally ...

Canada's new obesity guidelines signal a shift in food consumption, with GLP-1 drugs impacting how and what Canadians—especially youth—eat.

I’m Kelly Grant, a health reporter with The Globe and Mail. Yesterday, the Canadian Medical Association Journal published the first new guideline on the treatment of childhood obesity in nearly 20 ...

BMO Capital Markets analyst Evan Seigerman said Pfizer’s discontinuation of its GLP-1 pill sends the company back to the starting block as its other obesity drugs are all in the early stages of ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

A new Canadian guideline urges lifestyle interventions for obese children but also says today's new drugs might help kids ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

The two obesity market leaders, with their blockbuster injectables, have left room for an oral, or pill, market to be a new meaningful target for newer players, according to investors. Lilly is the ...

GLP-1s like Ozempic, as well as weight-loss surgery, are among the recommendations to treat childhood obesity in the first guideline update in Canada in almost 20 years.